Exposing the Hidden Costs: Hospitals Charging 500% More for Medicines

By Staff Writer

August 8, 2023

A recent analysis by The Moran Company has shed light on an alarming trend in the healthcare industry. On average, hospitals are charging a staggering 500% of what they paid for medicines. This practice is not only driving up costs for patients, but it’s also padding the profits of hospitals, insurers, and PBMs at the patient’s expense.

The study analysed 20 medicines and found that hospitals charged between two to seven times more than what they paid for them. This trend was initially identified in 2018 and has continued ever since. Even after negotiations with commercial payers, hospitals are still reimbursed almost 200% of what they paid to acquire the medicine.

Stephen J. Ubl, president and CEO of PhRMA, stated, “Hospital markups are driving up patients’ out-of-pocket costs, which particularly hurts patients living paycheck-to-paycheck and those in need of extensive medical care.”

Interestingly, despite a strong focus on drug spending, nearly 30% of every healthcare dollar in the United States is attributed to hospitals. Almost four times more is spent on hospitals than on retail prescription medicines annually, a trend predicted to continue indefinitely.

The study also pointed out that nearly 60% of all U.S. hospitals participate in the 340B drug pricing program, where medicines are purchased at substantial discounts. However, it’s estimated that these hospitals are reimbursed almost three times the discounted 340B price of a medicine.

As discussions continue on healthcare costs and affordability, policymakers must consider the increasing role hospitals play in driving costs for patients and the broader healthcare system.

Reference url

Recent Posts

EU Life Sciences Strategy
         

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?

The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.

Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #Innovation

ticagrelor data integrity
          

Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials

🔍 Are we truly getting the full story on high-cost medications like ticagrelor?

A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.

Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.

#SyenzaNews #HealthEconomics #Pharmaceuticals #MarketAccess

self-care public health
    

The Value of Self-Care in Public Health: Insights and Implications for Europe

🌍 Are we overlooking the power of self-care in Europe’s public health strategy?

The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.

Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.